BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (June 2014)
23 slides from BioSpecifics Technologies's investor presentation, Jun 2, 2014
Slide 1: Innovators in the development & commercialization of injectable collagenase
- d = - . \ a? al Innovators in the development DU & commercialization of _ INJECTABLE COLLAGENASE —_—*~., . BioSpecifics June 2014
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”
Slide 3: Corporate Overview
Corporate Overview BioSpecifics is a profitable, commercial-stage biopharma company maximizing the potential of injectable collagenase for multiple indications XIAFLEX® (collagenase clostridium histolyticum or CCH) is now marketed for two indications in the U.S. by strategic partner, Auxilium Pharma
Slide 4: Vast Therapeutic Potential of CCH
Vast Therapeutic Potential of CCH CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications: Dupuytren’s contracture’ Froze
Slide 5: Approved Indications
Approved Indication: Dupuytren’s Contracture Peyronie’: Benes a Sobi to file MAA for approval in EU Source: Auxiium Pharmaceuticals, Inc.
Slide 6: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand Definition and One or more fingers caused to contract toward the palm Key Complications Limits range of motion of the fingers often resulting in physical disability and impaired quality of life First and Only pDeeand Aut Ap
Slide 7: Label Expansion Opportunity
Label Expansion Opportunity » SDI Health LLC estimates 35 to 40% of Dupuytren’s contracture surgeries in U.S. are performed to treat two or more cords Pre-treatment: concurrently PDUFA date: October 20, 2014 ~ FDA to decide on sBLA, submitted by Auxilium, for XIAFLEX label expansion to allow multipl
Slide 8: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease Excess of inelastic collagen causing penile curvature deformity Definition & Results in pain with erection, penile shortening, indentations, erectile Key Complications dysfunction and/or difficulty with sexual intercourse Potential loss of self-esteem and depression fo
Slide 9: Launch Progress
Launch Progress Focused, disciplined product rollout 5,000-6,500 patients receive invasive treatment for Peyronie’s disease each year (surgery or verapamil injections ) ~400 urologists performed about 90% of PD surgeries Initial target is top ~235 of these urologists REMS certification of urologists
Slide 10: Launch Progress Cont.
Launch Progress Cont. Reimbursement approval by payers (Auxilium Advantage) All eight Medicare beneficiaries confirmed coverage at policy level; 15 major commercial health plans have approved patients for treatment Listed as 'medically necessary’ in Clinical Policy Bulletin, when administered under
Slide 11: XIAFLEX Pipeline Programs
XIAFLEX Pipeline Programs Indications | Preclinical | Phase 1 | Phase2 | Phase3 | Marketed pezen Top-line data expected in 1Q15 Shoulder i ia peanine | chien s04final study reportin 2034 a Chien-804 final study report in 2Q14 Lipoma fi hae *) Human Initiate placebo-controlled trial in 2Q14 Lipoma ce
Slide 12: CCH for Canine and Human Lipomas
CCH for Canine and Human Lipomas BioSpecifics-Managed Programs Encapsulated deposits of benign fatty tumors Definition and . Detected as bulges under the skin that occur in both humans and dogs Key Complications Can be serious health problem in dogs, restricting motion in older dogs Potential to be
Slide 13: Chien-804 Placebo-Controlled Phase 2 Trial in Canines
Chien-804 Placebo-Controlled Phase 2 Trial in Canines BioSpecifics reported data from placebo-controlled, randomized Phase 2 trial for CCH in canines with benign subcutaneous lipomas Study did not meet primary endpoint but demonstrated benefit in secondary measures: Responder analysis: » Visible sur
Slide 14: Dose Escalation Phase 2 Clinical Trial in Humans
Dose Escalation Phase 2 Clinical Trial in Humans BioSpecifics reported data from open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combinin
Slide 15: CCH for Uterine Fibroids
CCH for Uterine Fibroids Study Results Expected in 4Q14 Benign tumors with significant co- Definition & morbidities Key Complicati Pain, decreased fertility, miscarriage, ey Complications heavy menstrual bleeding and frequent urination Potential to be Primary indication for hysterectomy in 000 025 0
Slide 16: CCH for Frozen Shoulder Syndrome
CCH for Frozen Shoulder Syndrome Top-line Data from Phase 2b Study Expected in 1Q15 Inflammation and thickening of shoulder capsule due to collagen accumulation Key Complications Limits the range of motion of the shoulder and painful Potential to be Common available treatment option is Only Approved
Slide 17: Statistically Significant CCH Dose Response in Phase 2a Study
Statistically Significant CCH Dose Response in Phase 2a Study 1 1 Statistically significant improvements in 60; | nalscopai | 1 corward Flexion both the 0.58 mg(1mL) and 0.58 0} El eee Ca Shoulder Abduction mg(2mL) cohorts over baseline scores Extemal Rotation vs. the exercise-only group: 40 | 2 In
Slide 18: CCH for Cellulite
CCH for Cellulite Top-line Data from Phase 2a Study Expected in 4Q14 Definition Significant Market Opportunity as First Nonsurgical Therapy Top-line Data from Phase 2a Study Expected in 4Q14 Phase 2a Study Based on Positive Data from Phase 1b Trial Source of data: Auxilium Pharmaceuticals, Inc. Skin
Slide 19: Auxilium Partnership for Development and Commercialization of CCH
Auxilium Partnership for Development and Commercialization of CCH >$42.6M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Auxilium Opt-in Rights Milestone Payments from AUXL Partnerships Over $42M total received in licensing, sublicensing, milestone, COGS, and royalty paymen
Slide 20: Corporate Highlights
Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in U.S. until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 Peyronie’s Disease: Auxil
Slide 21: Consistently Profitable Annually
Consistently Profitable Annually 1Q14 Financial Highlights For the quarter For the year ended ended 03/31/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments $ 16,907,795 $ 12,591,825 Income Statement Revenues $ 2,761,279 $ 14,467,240 Other income 8,121 26,202 Costs and
Slide 22: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Steady Momentum in BioSpecifics-Managed Indications Upcoming Milestones *Human QO Initiate placebo-controlled trial in 2Q14 Lipomas Q Complete enrollment in placebo-controlled trial in 4Q14 *Canine Q Chien-804 final study report in 2Q14 Lipomas QO Final report trigger
Slide 23: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE —_—-~ . BioSpecifics ronenang
BioSpecifics Technologies — Investor Presentation (June 2014) on 6ix